share_log

康泰生物(300601.SZ):吸附无细胞百白破灭活脊髓灰质炎和b型流感嗜血杆菌联合疫苗(五联苗)目前处于Ⅰ期临床试验阶段

Shenzhen Kangtai Biological Products (300601.SZ) is currently in Phase I clinical trial for its adsorbed non-cellular pertussis, inactivated poliomyelitis, and Haemophilus influenzae type b conjugate vaccine (pentavalent vaccine).

Gelonghui Finance ·  Jul 26 08:05

Shenzhen Kangtai Biological Products (300601.SZ) stated on the investor interaction platform on July 26 that the company's adsorbed combined vaccine for diphtheria, tetanus, pertussis, poliomyelitis and type b influenza (pentavalent vaccine) is currently in Phase I clinical trials. If the product development and registration progress meets the information disclosure standards, the company will fulfill information disclosure obligations in accordance with relevant laws and regulations.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment